Abstract. A review is made of the literature on central nervous system involvement in systemic lupus erythematosus (CNS-SLE). Particular attention is focused on lupus myelopathy. Referring to two well-documented personal cases, the authors describe the characteristic multisystem involvement, protean clinical pattern, serum and cere brospinal fluid changes, histoimmunologic findings, response to corticosteroids and immunosuppressive agents and some prognostic features.
Involvement of the central nervous system in SLE patients is a rather common finding. Quite similar to syphilitic nerve damage there also exists a large variety of clinical expressions. The incidence of neuropsychiatric disorders reported in the literature varies between 10 and 60 per cent, depending on the length of follow-up, thoroughness of neurological examination and mode of treatment (Bas & Vachten heim, 1963; Berry & Hodges, 1965) .
The occurrence of mental disorders in SLE patients had already been reported by Hebra and Kaposi in 1875. Hemiplegia and aphasia were described by Osler in 1903. Daly, in 1945 , described a state of 'toxic delirium' with prostration, anxiety, irritability and disorientation in several of his SLE patients. A full account of the large range of neuropsychiatric manifestations was presented by Sedgwick and Von Hagen in 1948 . Three years later Russel, Haserick and Zucker (1951) reported severe episodes of seizures in 15 per cent of a series of 144 patients. In 1952 Heptinstall and Sowry presented the first detailed paper on peripheral neuritis. Weil, in 1955, published a well-documented case report on subarachnoid haemorrhage. Scheinberg, in 1956 , drew attention to the rare occurrence of Guillain-Barre-like symptoms.
In the recent literature cranial nerve involvement is mentioned in approxi mately 15 to 20 per cent. Chorea is exceptional. Bennahum and Messner (1975) , reviewing the literature on this subject, found only 29 cases. Brandt and Lessell (1978) state that migrainous phenomena, such as throbbing headache of hemi cranial onset and visual hallucinations, are frequently observed during exacerba tions of SLE. In periods of remission these symptoms spontaneously disappear. These authors also indicate that corticosteroids are more effective in bringing about relief than conventional antimigraine therapy.
Approximately one-third of all patients with CNS involvement show psychotic depressive reactions. Less frequently catatonic, paranoid and manic states are observed. Bennahum and Messner (1975) detected organic psychiatric symptoms (delirium, hallucinations, etc.) in 16·6 and functional psychiatric symptoms (depression, anxiety, etc.) in 53·7 per cent of a series of 54 patients with CNS SLE. Sergent, Lockshin and Klempner (1975) state that functional psychoses are likely to become aggravated by high-dose corticosteroids. They suggest that minimal effective doses should be administered in combination with psychotropic drugs.
Central nervous system involvement occurs typically at a moment of acute exacerbation of lupus erythematosus. O'Connor and Musher (1966) state that only very few patients on ambulant care exhibit signs of CNS involvement. Exceptionally CNS disorders may be the first clinical manifestation of LE. Silverstein (1963) described five cases with an 'acute cerebral insult' as initial symptom of SLE. Krankenhagen, Cohnen and Lehmann (1975) also described severe neurological disorders as initial clinical expression of LE (Table II) .
Diagnosis
It may at times be difficult to decide whether neuropsychiatric symptoms are directly related to SLE (Stern & Robbins, 1960) or rather a consequence of long-term therapy with corticosteroids or of severe nephropathy. When reviewing the literature we found that early diagnosis of CNS-SLE was very frequently mistaken. This emphasises the diagnostic value of additional information that may be derived from recently developed techniques such as histoimmunology (Johnson & Richardson, 1968) .
Laboratory investigations
Cerebrospinal fluid: in the acute stage of CNS-SLE, CSF shows pleocytosIs (rarely exceeding 200 cells/mm3) and moderately increased protein. These changes, however, do not reflect the severity of the disease nor do they have prognostic value. In the acute stage of CNS involvement the titers of CSF-C4 (complement component 4) and CSF IgG are often significantly decreased (Petz, Sharp & Cooper, 1971; Levin, Findenberg & Petz, 1972; Hadler, Gerwin & Frank, 1973) . This clearly speaks in favour of a direct implication of immune mechanisms in CNS manifestations of LE. The fact that antineuron antibodies may be isolated in 40 per cent of patients with central nervous involvement, but only in 10 per cent in patients without neurological signs further corroborates this concept.
Serum studies: during clinical exacerbations of SLE the complement com ponent C3 is frequently decreased. Concomitantly one observes high titers of circulating antinuclear antibodies and DNA/anti-DNA immune complexes. It is now thought that the latter may be trapped in the basement membrane of the choroid plexus where complement fixation may ensue (Burton, Duffie & Mudler, 1971) .
In recent years several authors have reported significantly increased levels of antiviral antibodies in LE patients without parallel changes in total serum IgG, IgA and IgM. This observation is compatible with a humoral hyperresponsiveness of SLE patients to a variety of viral antigens such as parainfluenza II and III and influenza A2 and B.
Other findings which will require further studies are the unexpectedly high incidence of lymphocytotoxic antibodies in most SLE patients and their relatives and the marked decrease or suppression of T-cell function. In fact, a dis equilibrium of thymus-dependent (T) and bone-marrow-dependent (B) lympho cyte function may well trigger some of the complex immunologic abnormalities in SLE patients.
With regard to histocompatibility it has been found that HLA-Bs is prevalent in 40 per cent of SLE patients as compared to 20 per cent in healthy controls.
Electroencephalography: the frequently recorded dominant beta-wave is com patible with diffuse encephalopathy; there exists, however, no direct correlation with the clinical symptomatology. Small, Mass, Kohler and Harbeck (1977) observed altered EEG pattern in about 80 per cent of their LE patients.
Brain scan: this technique is useful in identifying patients with decreased cerebral vascular flow and in distinguishing them from cases with steroid psychosis and functional mental disorders. Abnormal flow brain scans are obtained in about 50 per cent of LE patients with CNS involvement (Bennahum, Messner & Shoop, 1974; Small et al., 1977) .
Pathology
The histopathological studies reveal multiple small infarcts or haemorrhages with perivascular gliosis. An embolic aetiology can usually be excluded. The lesions are essentially confined to the cortex and brain stem. There exists a rather poor correlation between the clinical symptoms and anatomo-pathologic findings. Thus, some patients with minimal neuropsychiatric disorders have widespread CNS involvement and vice versa (Gold & Yahr, 1960) .
Prognosis
Spontaneous remission may be observed in as much as 40 per cent of the patients. In this context it appears difficult to assess the efficacy of drug therapy and to propose guide-lines for optimal dosage regimes of corticosteroids and immunosuppressive agents.
The prognosis of patients with neuropsychiatric signs depends essentially on the extent and severity of multiorgan disease. On the average three other systems are involved. Lupus nephritis, present in two-thirds of the patients, has long been the major cause of death. Since haemodialysis has become available, the average survival of patients with CNS-SLE now closely approaches the 10 years' limit and death now frequently results from CNS damage.
Transverse Myelopathy
This manifestation of central nervous system involvement is very rare. Until today 18 authors have reported a total of 26 cases (see Table III ). Spinal cord damage occurs mostly at a time of acute exacerbation of LE (Andrews, Cancilla & Kunin, 1970; Castaing, Vital & Cardinaud, 1970) . Onset is usually rapid, within a few hours. The most common neurological level is mid-thoracic (about 60 per cent) and the large majority of these patients present complete and irrevers ible paraplegia (Penn & Rowan, 1968) . In the remaining group of patients cervical and lumbar myelomalacia are about equally frequent and often cause only partial motor and sensor loss (Piper, 1953; Andrianakos, Duffy & Suzuki, 1975) . Occasionally transverse myelitis is the first manifestation of lupus erythe matosus. Granger (1960) reported a case of sudden transverse myelitis in a 25-year-old female who was treated with chloroquine and recovered completely within 4 months. In a case described by Siekert and Clark (1955) , acute myelo pathy also was the initial evidence of SLE; other systems became involved 2 years later only.
Cortisone treatment does not affect the course of lupus myelopathy but may induce prolonged remissions in other systems, particularly in combination with azathioprine.
Post-mortem examination reveals multiple small zones of myelomalacia in both the grey and white matter; arterioles may show some degree of fibrinoid degeneration. LE-specific lesions have not been described in the central nervous system. In evaluating the anatomopathological picture one should consider the possible changes induced by prolonged corticosteroid treatment. Upon admission the patient was irritable and lethargic, complained of vertigo, throbbing headache and diffuse myalgia. Temperature was 39·4°C. Physical examina tion revealed no sign of skin rash, arthritis or petechiae. The liver was slightly enlarged and tender, but there was no splenomegaly nor lymphadenopathy. Cardiac auscultation disclosed a soft apical systolic murmur; the ECG indicated flat T -waves. Roentgeno grams of the chest revealed slight pleural thickening. A barium enema, i.v. pyelogram and sinus X-ray films were normal. Malignancy could be ruled out. Laboratory investigations showed a markedly accelerated sedimentation rate of 98/I I5; haemoglobin was 9'2 g. Blood chemistry was unremarkable. ANA-titer was positive at 160; a complement fixation test with DNA was also strongly positive. LE cells could not be identified. Kidney biopsy demonstrated typical lupus nephritis with 'wire-loop' changes in the glomerular tufts. Prednisone treatment was started at an initial dosage of 80 mg per day and subsequently tapered to 10 mg per day.
Six months later, in April 1965, the patient again complained of vertigo and severe left hemicranial headache; neurological examination showed marked pyramidal signs. Latex test was positive. Within the next 6 months the neurological syndrome gradually worsened in spite of high dose prednisone and Imuran. In October 1965 a scaly erythe matous rash developed on the face and elbows; a skin biopsy showed typical lupus involve ment. The following year, in early June, the patient had another exacerbation. He was at that time febrile at 39'6°C, complained of minor visual disturbances, numbness and extreme fatigability in both lower extremities and difficulty in voiding. Within 8 hours of admission he developed paraplegia with a mid-thoracic sensory level. There was no sign of meningeal irritation; cerebellar function and cranial nerves were normal. Neurologic examination demonstrated marked hyperreflexia in both lower extremities with bilateral extensor plantar response; sensation of pin, touch, vibration and position below T 5 was abolished. CSF analysis disclosed pleocytosis ( 43 0 elements/mm3), increased protein (128 mg/loo ml) and normal glucose. Treatment consisted of prednisone 20 mg daily, combined with alternate courses of Imuran and Methotrexate. With this medication the patient entered a stage of remission; however, his neurological deficit remained unchanged. In December 1967, 18 months after spinal cord involvement, LE cells were identified for the first time.
Until 197 4 the patient remained in a state of remission, with occasional burst of fever, intermittent urinary infections and two episodes of arthralgia in both wrists and elbows. In February he was rehospitalised because of severe dyspnea which was con sidered to be due to lupoid pleuritis. Physical examination revealed a dilated bladder of 1600 ml capacity. Urodynamic investigations confirmed the diagnosis of unbalanced automatic neurogenic bladder in a state of severe chronic retention. The latter was attributed to repeated overdilation of the detrusor and concomitant functional bladder outlet obstruction. In view of these findings we initiated treatment with a cholinesterase inhibitor (distigmin bromide, 3 x 5 mg per day) in combination with an alpha-adrenergic inhibitor (phenoxybenzamine, 4 x 10 mg per day). Control cystosphincterometry, carried out 3 months later, showed non-inhibited detrusor contractions of 40 to 60 cmH20 and post-micturition residuals between 60 and 100 ml. Dyspnea had entirely disappeared and spirometry indicated a vital capacity of 3 I 50 ml and a maximal expiratory volume/second of 1620 ml. The patient was dismissed and remained fairly well until September 1975 when he developed severe seizures and entered a deep comatous state which persisted for several hours. When he regained consciousness he presented typical Cheyne-Stokes breathing and a left conjugate deviation of the head and the eyes. CSF analysis disclosed 128 mg of protein/IOo ml, 265 WBC/mm3 (59 per cent segmented and 27 per cent non-segmented neutrophils); culture was sterile. Serum anti-DNA anti bodies and direct Coombs' test were strongly positive.
Beta-I-C-globulin was 33 mg per cent and kidney biopsy showed marked glomerular deposits of immunoglobulin. Isotope clearance studies indicated a glomerular filtration rate of 9 4 ml/min/I'73 m2 and a renal plasma flow of 406 ml/min/I'73 m2• Over the following 3 weeks the patient gradually improved. In September 197 5 he was admitted to the department of rehabilitation medicine. Since that time he has suffered no further complications.
O. Y. (CP. 45°109).
In September 196 4 , at the age of 19, this female patient experienced sudden weakness in both legs with gradually intensifying sensor disturbance and loss of sphincter control. Upon admission physical examination was compatible with the diagnosis of Guillain-Barre syndrome. ESR was 60/107 mm. CSF revealed moderate pleocytosis; protein and glucose were within normal limits. In December of the same year the girl developed a circumscribed alopecia in the occipital region. She was put on corticosteroids and recovered nearly normal neurological function. In February 196 5 the diagnosis of lupus erythematosus was clinically established and con firmed by the finding of abundant LE-cells on three occasions, a significantly increased titer of antinuclear antibodies and concomitant hypocomplementemia. Prednisone was increased to 80 mg per day. Within 5 weeks motor strength in both legs considerably improved. Sensation to pin, touch and vibrations was normal. In January 1969 recurrent attacks of painful swelling were observed in several joints, the wrists and knees being mainly affected. Progressive muscle wasting and general fatigue further characterised the clinical picture. Urinary retention was diagnosed 2 days later. Erythematous scaly patches developed on face, neck and both elbows. The abdomen was found very tender on palpation. Within 5 hours after admission to the emergency department the patient complained of numbness and tingling in both feet which rapidly spread to the thighs and abdomen. Within less than an hour complete flaccid paraplegia was diagnosed. The following day both upper extremities became involved. The girl complained of visual difficulties, had a slight convergent strabism and a horizontal nystagmus. CSF pressure was 4 0 cmH20; there was marked pleocytosis of 1600 elements/mm3, mostly polynuclears. Protein was moderately increased, glucose normal and culture sterile. Serum analysis revealed anti-DNA antibodies at a titre of 1/8 and hypocomplementemia. ESR was 50/84 mm.
A gaz myelography was carried out 12 hours after admission and disclosed no pathological findings. Kidney biopsy confirmed the diagnosis of lupus nephritis. Treatment consisted of intraspinal administration of 50 mg of Imuran (azathioprine) and 10 mg of Methotrexate (amethopterine). Prednisone was administered at a dose of 10 to 20 mg per day. The cranial nerve disorders totally subsided, but complete flaccid paraplegia below T 5 remained unchanged. The subsequent follow-up remained un eventful but was complicated by multiple pressure sores on the sacrum and both buttocks. Plastic surgery was necessary on three occasions. In 1973 a check-up still showed high titres of anti-DNA antibodies, but LE-cells could no longer be identified. A chest x ray revealed bilateral aseptic osteonecrosis of the head of the humerus. Otherwise the patient was in satisfactory general condition. The autonomous neurogenic bladder had so far caused no complication; the patient was continent and had sterile urine. Within the past four years there have been no acute exacerbations. Prednisone treatment is presently continued at a low maintenance dose of 3 mg per day.
Conclusions
There have been three major milestones in the understanding and management of systemic lupus erythematosus.
The first one, Hargrave's description of the LE-cell preparation in 1948, greatly contributed to improved diagnosis; the second, introduction of cortico steroids in the early fifties, had a considerable impact on the clinical manifesta tions and prognosis; the third, recognition of the autoimmune character of the disease and identification of various immune complexes within the vessel walls of several organ systems, largely contributed to better understanding of the pathogenesis.
Due to early diagnosis, comprehensive management and prevention of com plications, such as urinary infection and pressure sores, the survival rate of SLE patients has considerably improved within the last decade. eNS involvement, which is known to occur in the later stages of SLE, is therefore likely to be diagnosed with increasing frequency. In fact, the morbidity and mortality due to central nervous system damage now closely approach the ones of lupus nephritis. Spinal cord involvement remains exceptional. These patients should benefit from the same nursing care which we offer to cases with traumatic lesions, especially with regard to neurogenic bladder training, prevention of pressure sores and respiratory therapy.
SUMMARY
Neurologic and psychiatric disorders are present in approximately 30-40 per cent of patients with disseminated lupus erythematosus. eNS involvement is second only to uremia as a cause of death. Seizures are the single most common symptom (15 per cent). Spinal cord lesions are exceptional. So far 26 cases have been reported by 18 authors. Life-expectancy of SLE patients has considerably improved within the last decade as a result of early diagnosis and combined therapy with corticosteroids and immunosuppressive agents. Renal death may now be prevented by dialysis. Therefore an increasing proportion of patients enter the late stage of the disease, where eNS-involvement is a common finding. We emphasise the need for early hospitalisation of patients with spinal cord involve ment in a specialised unit where turning beds, intermittent catheterisation and comprehensive motor rehabilitation are available.
RESUME
Des perturbations d'ordre neurologique ou psychiatrique s'observent chez 30-40% des patients atteints d'un lupus erythemateux dissemine. Les lesIons du systeme nerveux central occupent Ie deuxieme rang parmi les causes de mortalite, immediatement apres l'insuffisance renale par glomerulopathie lupique. Les convulsions epileptiformes sont Ie symptome Ie plus courant (15%), l'atteinte de la moelle epiniere est exceptionnelle. Jusqu'a ce jour, 26 cas seulement ont ete rapportes dans la litterature par 18 auteurs. L'esperance de vie des sujets atteints de lupus erythemateux s'est considerablement amelioree au cours de la derniere decennie grace aux nouveaux moyens d'exploration de laboratoire permet tant un diagnostic precoce et a l'introduction d'une therapeutique combinee associant les corticosteroides aux agents immunosuppresseurs.
Dans ce contexte, une proportion accrue de patients entre dans la phase tardive de la maladie au cours de laquelle les lesions du systeme nerveux central sont particulierement frequentes.
Nous insistons sur l'importance d'une hospitalisation precoce des sujets atteints de myelopathie LE dans un service specialise, afin d'eviter Ie crotege des complications (escarre, infecti.on urinaire, etc.) et d'assurer un programme de reeducation fonctionnelle optimal. 
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